Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MicroB2: Microbiome Modulation in Insulin Resistance
NCT02127125Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Apr 2014
- Primary completion
- Sep 2018
- Modality
- Polymer-based Nanoparticles, Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sevelamer carbonate, bifidobacterium longum R0175 + oligofructose in type 2 diabetes mellitus (T2DM), obesity, sponsored by UT Health San Antonio. Started Apr 2014; status: completed.
02
Drugs
sevelamer carbonatebifidobacterium longum R0175 + oligofructose
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02127125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127125.